1. Scrip
  2. >>Business

GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back

Safety Profile Will Be Battleground

 
• By Andrew McConaghie

AstraZeneca and FibroGen hit another safety roadblock with roxadustat, while GSK is hoping it might catch up with its rivals in the US.

Entrance to FDA headquarters in Maryland
After a near-unanimous vote against approval from experts, the US FDA looks likely to reject roxadustat.

Just one day after AstraZeneca and FibroGen received a knock-back from a US Food and Drug Administration advisory panel on their oral anemia treatment roxadustat, GlaxoSmithKline has unveiled data which could help it overtake its rivals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.